Shares in Straumann Holding show a positive technical chart pattern over the medium term. The timing to jump back on the rising trend seems good. Investors have an opportunity to buy the stock and target the CHF 809.5.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The close medium term support offers good timing for purchasing the stock.
Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The group usually releases upbeat results with huge surprise rates.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Based on current prices, the company has particularly high valuation levels.
With an expected P/E ratio at 37.29 and 30.18 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Subsector Medical Equipment, Supplies & Distribution
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.